CE
Background
Interim CFO at Verdant Biosciences, currently supporting the team through a Phase I readout and pre-Series A planning. Previously CFO at Kestrel Biopharma where I led our £18m Series A, and I hold non-executive roles at Arclight Pharma and Quill Bio across audit and remuneration. My focus is UK oncology and rare diseas…
Experience15 yrsCompanies8
Career History
Jan 2025 – Present1 yr 6 moNED (Audit Remcom Chair) at Arclight Pharma
Aug 2024 – Present1 yr 11 moInterim CFO at Verdant Biosciences
Pre-Series A9 FTEsOncology · ADC platform
Interim CFO at a 9-person Cambridge oncology spinout building data room and KPI pack for a £20M Series A targeted Q2 2026.
Aug 2024 – Present1 yr 11 moInterim CFO at Solivant Therapeutics
Series A22 FTEsSolid tumour immunotherapy
Interim CFO covering maternity at a Series A oncology biotech, owning the £14M extension round close and HMRC R&D tax credit refile.
Jul 2024 – Present2 yrNon Executive Director at Quill Bio
Education
BEng, Engineering — Saltmoor College (1985–1988)